MX2023002695A - Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. - Google Patents

Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo.

Info

Publication number
MX2023002695A
MX2023002695A MX2023002695A MX2023002695A MX2023002695A MX 2023002695 A MX2023002695 A MX 2023002695A MX 2023002695 A MX2023002695 A MX 2023002695A MX 2023002695 A MX2023002695 A MX 2023002695A MX 2023002695 A MX2023002695 A MX 2023002695A
Authority
MX
Mexico
Prior art keywords
variants
vegf
aav2
conbercept
adeno
Prior art date
Application number
MX2023002695A
Other languages
English (en)
Inventor
Guangping Gao
Phillip Tai
Claudio Punzo
Haijiang Lin
Original Assignee
Univ Massachusetts
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Massachusetts filed Critical Univ Massachusetts
Publication of MX2023002695A publication Critical patent/MX2023002695A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering N.A.
    • C12N2310/141—MicroRNAs, miRNAs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Ophthalmology & Optometry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)

Abstract

spectos de la divulgación se refieren a composiciones y métodos para expresar el agente anti-factor de crecimiento de células endoteliales vasculares (VEGF) en una célula o sujeto. En algunas modalidades, la divulgación proporciona rAAV que comprenden una proteína de la cápside (por ejemplo, variantes de AAV2, variantes híbridas de AAV2/3, variantes de AAV8, etc.), y un transgén que codifica un agente anti-VEGF (por ejemplo, KH902) y una o más secuencias reguladoras. En algunas modalidades, las composiciones descritas en la presente son útiles para tratar sujetos que tienen enfermedades asociadas con angiogénesis o actividad/señalización aberrante de VEGF.
MX2023002695A 2020-09-03 2021-09-02 Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo. MX2023002695A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063074361P 2020-09-03 2020-09-03
US202163179700P 2021-04-26 2021-04-26
PCT/US2021/048917 WO2022051537A1 (en) 2020-09-03 2021-09-02 Adeno-associated virus for delivery of kh902 (conbercept) and uses thereof

Publications (1)

Publication Number Publication Date
MX2023002695A true MX2023002695A (es) 2023-05-19

Family

ID=80491540

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2023002695A MX2023002695A (es) 2020-09-03 2021-09-02 Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo.

Country Status (10)

Country Link
US (1) US20230340529A1 (es)
EP (1) EP4208478A1 (es)
JP (1) JP2023540094A (es)
KR (1) KR20230061441A (es)
AU (1) AU2021336425A1 (es)
BR (1) BR112023003548A2 (es)
CA (1) CA3192736A1 (es)
IL (1) IL300864A (es)
MX (1) MX2023002695A (es)
WO (1) WO2022051537A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019126329A1 (en) 2017-12-19 2019-06-27 Akouos Llc Aav-mediated delivery of therapeutic antibodies to the inner ear

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1767546B1 (en) * 2004-06-08 2012-03-07 Chengdu Kanghong Biotechnologies Co., Ltd. Angiogenesis-inhibiting chimeric protein and the use
CA3107182A1 (en) * 2013-07-12 2015-01-15 Iveric Bio, Inc. Methods for treating or preventing ophthalmological conditions
CA3021949C (en) * 2015-04-24 2023-10-17 University Of Massachusetts Modified aav constructs and uses thereof

Also Published As

Publication number Publication date
US20230340529A1 (en) 2023-10-26
IL300864A (en) 2023-04-01
WO2022051537A1 (en) 2022-03-10
JP2023540094A (ja) 2023-09-21
BR112023003548A2 (pt) 2023-04-04
KR20230061441A (ko) 2023-05-08
AU2021336425A1 (en) 2023-03-16
EP4208478A1 (en) 2023-07-12
CA3192736A1 (en) 2022-03-10

Similar Documents

Publication Publication Date Title
US11491242B2 (en) AAV vectors targeted to the central nervous system
US20190127424A1 (en) Capsid-modified raav vector compositions and methods therefor
AU2020200041A1 (en) Capsid-modified, rAAV3 vector compositions and uses in gene therapy of human liver cancer
KR102554850B1 (ko) 최적화된 인간 응고 인자 viii 유전자 발현 카세트 및 그의 용도
US20230091502A1 (en) Optimized human clotting factor ix gene expression cassettes and their use
JP6924441B2 (ja) てんかん治療のためのアデノ随伴ウイルスビリオン
CN101511373A (zh) 用于基因治疗的修饰的因子viii和因子ix基因和载体
MX2022002961A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
MX2023002695A (es) Virus adeno-asociado para la administración de kh902 (conbercept) y usos del mismo.
CO2022015313A2 (es) Variantes de cápsides de aav y usos de los mismos
ES2729872T3 (es) Terapias basadas en la transcriptasa inversa de la telomerasa
UY38881A (es) Métodos de tratamiento de enfermedades neovasculares oculares utilizando variantes de aav2 que codifican aflibercept
MX2022002960A (es) Metodos para tratar enfermedades neovasculares oculares usando variantes de aav2 que codifican para aflibercept.
US20230136849A1 (en) Capsid-modified raav vector compositions and methods therefor
Yoon et al. Decorin expression from oncolytic adenovirus potentiate antitumor efficacy via mitochondrial apoptosis in cancer cells
Kasala et al. Systemic Delivery of Helical Polypeptide Induces Tumor-Specific Apoptosis
Kim et al. Adenovirus-Mediated Expression of Relaxin for Treatment of Scar Remodeling
Tisdale et al. Clinical Trials Spotlight
Oh et al. A Hypoxia-Responsive Oncolytic Adenovirus Expressing Secretable TRAIL for Cancer Gene Therapy
KR20210148101A (ko) 폴리뉴클레오티드
Class et al. Patent application title: CAPSID-MODIFIED RAAV VECTOR COMPOSITIONS AND METHODS THEREFOR Inventors: Arun Srivastava (Gainesville, FL, US) Arun Srivastava (Gainesville, FL, US) George V. Aslanidi (Gainesville, FL, US) Sergei Zolotukhin (Gainesville, FL, US) Sergei Zolotukhin (Gainesville, FL, US) Mavis Agbandje-Mckenna (Gainesville, FL, US) Kim M. Van Vliet (Gainesville, FL, US) Li Zhong (Boxborough, MA, US) Lakshmanan Govindasamy (Gainesville, FL, US) Assignees: University of Florida Research Foundation Inc.
RU2019103983A (ru) Новые капсидные белки адено-ассоциированного вируса
KR20240000573A (ko) 혈우병에서 혈우병성 관절병증을 예방 및/또는 치료하기 위한 방법 및 수단